Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | STAT3 | P40763 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136691 | 1.00 | ALOX15 (0.74) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Bisabolol Acetate SCHEMBL4279285 | 0.85 | LMNA (1.00) | ALOX15LMNACYP3A4STAT3MEN1 | |
| SCHEMBL13177710 | 0.84 | ALOX15 (0.72) | ALOX15LMNACYP3A4STAT3MEN1 | |
| SCHEMBL8510625 | 0.82 | LMNA (0.70) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Levomenol SCHEMBL14515491 | 0.79 | ALOX15 (1.00) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Levomenol SCHEMBL1245143 | 0.79 | ALOX15 (1.00) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Bisabolol SCHEMBL13220166 | 0.79 | ALOX15 (1.00) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Levomenol SCHEMBL20838984 | 0.79 | ALOX15 (1.00) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Levomenol SCHEMBL4259122 | 0.79 | ALOX15 (1.00) | ALOX15LMNACYP3A4STAT3MEN1 | |
| Levomenol SCHEMBL2728600 | 0.79 | ALOX15 (1.00) | ALOX15LMNACYP3A4STAT3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | BASF SE (DE) | 2010-09-02 | — | — | US | claimed |
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | BASF SE (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | FHIT, FDPS, FNTA | ALOX15 292/4885LMNA 1546/4885CYP3A4 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.